The COVID-19 pandemic has highlighted the obstacles posed by intellectual property and in particular patents on vaccine design, manufacture, and clinical testing. To date, there are more than 100 patents related to mRNA technology, encompassing not just the production of mRNA but also various elements crucial for vaccine development, including lipid nanoparticles for encapsulation and technology for optimizing RNA sequences
Navigating the intricate web of patents poses a significant challenge to research efforts, potentially causing delays in the development of crucial vaccines. While patents are relevant when a company intends to market a product, access to technology should be possible and encouraged for non-commercial research purpose.
With mRNA playing a more prominent role in designing and testing HIV vaccines products, understanding and navigating this landscape is now essential for HIV vaccine research and development (R&D).
To tackle the challenges associated with intellectual property management in R&D, the IAS HIV Vaccine Industry Partnership together with Global HIV Vaccine Enterprise are hosting this event to give an overview of the complexity of intellectual property related to vaccine technologies, to highlight the obstacles hindering the sharing of intellectual property for vaccine development, and to gain insights into effective strategies for overcoming these barriers.
Navigating the intricate web of patents poses a significant challenge to research efforts, potentially causing delays in the development of crucial vaccines. While patents are relevant when a company intends to market a product, access to technology should be possible and encouraged for non-commercial research purpose.
With mRNA playing a more prominent role in designing and testing HIV vaccines products, understanding and navigating this landscape is now essential for HIV vaccine research and development (R&D).
To tackle the challenges associated with intellectual property management in R&D, the IAS HIV Vaccine Industry Partnership together with Global HIV Vaccine Enterprise are hosting this event to give an overview of the complexity of intellectual property related to vaccine technologies, to highlight the obstacles hindering the sharing of intellectual property for vaccine development, and to gain insights into effective strategies for overcoming these barriers.